Morgan Stanley
IRD

Morgan Stanley’s Opus Genetics IRD Stock Holding History

Morgan Stanley’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.91M Buy
464,900
+425,378
+1,076% +$1.98M ﹤0.01% 4876
2026
Q1 		$180K Buy
39,522
+10,857
+38% +$37.6K ﹤0.01% 5918
2025
Q4 		$57.6K Buy
28,665
+59
+0.2% +$120 ﹤0.01% 6390
2025
Q3 		$47.2K Hold
28,606
– – ﹤0.01% 6422
2025
Q2 		$26.9K Hold
28,606
– – ﹤0.01% 6555
2025
Q1 		$28.1K Hold
28,606
– – ﹤0.01% 6452
2024
Q4 		$34K Sell
28,606
-27,490
-49% -$31.6K ﹤0.01% 6405
2024
Q3 		$73.5K Sell
56,096
-9
-0% -$14 ﹤0.01% 6107
2024
Q2 		$85.8K Sell
56,105
-9
-0% -$16 ﹤0.01% 6014
2024
Q1 		$113K Hold
56,114
– – ﹤0.01% 5938
2023
Q4 		$169K Buy
56,114
+26,786
+91% +$79.2K ﹤0.01% 5756
2023
Q3 		$98.2K Sell
29,328
-1,520
-5% -$6.1K ﹤0.01% 5902
2023
Q2 		$134K Buy
30,848
+2,234
+8% +$10.6K ﹤0.01% 5815
2023
Q1 		$107K Sell
28,614
-4,527
-14% -$16.3K ﹤0.01% 5980
2022
Q4 		$117K Buy
33,141
+538
+2% +$1.42K ﹤0.01% 5911
2022
Q3 		$66K Sell
32,603
-2,063
-6% -$4.45K ﹤0.01% 6279
2022
Q2 		$67K Buy
34,666
+11,341
+49% +$25.8K ﹤0.01% 6475
2022
Q1 		$76K Buy
23,325
+2,000
+9% +$6.84K ﹤0.01% 6483
2021
Q4 		$80K Buy
21,325
+2,165
+11% +$8.68K ﹤0.01% 6569
2021
Q3 		$99K Buy
19,160
+5,500
+40% +$25.4K ﹤0.01% 6386
2021
Q2 		$72K Buy
13,660
+7,504
+122% +$37.3K ﹤0.01% 6498
2021
Q1 		$36K Buy
6,156
+5,456
+779% +$50.7K ﹤0.01% 6506
2020
Q4 		$5K Buy
700
+666
+1,959% +$4.6K ﹤0.01% 6778
2020
Q3 		$0 Hold
34
– – ﹤0.01% 6850
2020
Q2 		$0 Hold
34
– – ﹤0.01% 6751
2020
Q1 		$0 Sell
34
-2
-6% -$17 ﹤0.01% 6736
2019
Q4 		$0 Sell
36
-3
-8% -$23 ﹤0.01% 6792
2019
Q3 		$0 Sell
39
-27
-41% -$376 ﹤0.01% 6780
2019
Q2 		$2K Buy
66
+30
+83% +$678 ﹤0.01% 6480
2019
Q1 		$1K Buy
36
+2
+6% +$66 ﹤0.01% 6545
2018
Q4 		$2K Sell
34
-2
-6% -$117 ﹤0.01% 6446
2018
Q3 		$3K Buy
36
+2
+6% +$155 ﹤0.01% 6528
2018
Q2 		$2K Sell
34
-2
-6% -$176 ﹤0.01% 6560
2018
Q1 		$2K Buy
36
+2
+6% +$182 ﹤0.01% 6507
2017
Q4 		$3K Buy
+34
New +$3.45K ﹤0.01% 6412
2017
Q3 		– Sell
-77
Closed -$11K – 6630
2017
Q2 		$11K Buy
+77
New +$15K ﹤0.01% 6223
2016
Q3 		– Sell
-2
Closed – – 6576
2016
Q2 		$0 Hold
2
– – ﹤0.01% 6677
2016
Q1 		$0 Hold
2
– – ﹤0.01% 6739
2015
Q4 		$0 Buy
+2
New +$425 ﹤0.01% 6821
2015
Q1 		– Sell
-525
Closed -$176K – 6674
2014
Q4 		$176K Buy
+525
New +$181K ﹤0.01% 5302
2014
Q3 		– Sell
-2,575
Closed -$1.07M – 6673
2014
Q2 		$1.07M Buy
2,575
+1,824
+243% +$829K ﹤0.01% 3998
2014
Q1 		$389K Buy
751
+684
+1,021% +$370K ﹤0.01% 4727
2013
Q4 		$17K Buy
+67
New +$14.1K ﹤0.01% 5914

Other funds holding IRD

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley's IRD Position: Q2 2026 in Review

Morgan Stanley increased its Opus Genetics (IRD) stake by 1,076% in Q2 2026, buying an estimated $1.98M and bringing the position to 464,900 shares worth $1.91M. The position accounts for ﹤0.01% of the portfolio, ranked #4876.

Morgan Stanley first reported a position in IRD in Q4 2013 and has held it in 43 quarters since. 103 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

  • Morgan Stanley held 464,900 shares of Opus Genetics worth $1.91M as of Q2 2026.
  • Morgan Stanley bought 425,378 Opus Genetics shares in Q2 2026, an estimated $1.98M.
  • Opus Genetics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4876 holding.
  • Morgan Stanley first reported a position in Opus Genetics in Q4 2013 and has held it in 43 quarters since.
  • 103 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.